About MeiraGTx
MeiraGTx is a company based in New York (United States) founded in 2015.. The company has 381 employees as of December 31, 2024. MeiraGTx offers products and services including Riboswitch Platform, Vector Optimization, and End-to-end Manufacturing Ecosystem. MeiraGTx operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Biogen, Alnylam and ATAI, among others.
- Headquarter New York, United States
- Employees 381 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Meiragtx Holdings Plc
-
Annual Revenue
$33.28 M137.42as on Dec 31, 2024
-
Net Profit
$-147.79 M-75.89as on Dec 31, 2024
-
EBITDA
$-151.38 M-22.75as on Dec 31, 2024
-
Latest Funding Round
$30 M (USD), Post-IPO
Oct 30, 2023
- Investors
-
Employee Count
381
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MeiraGTx
MeiraGTx is a publicly listed company on the NASDAQ with ticker symbol MGTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MeiraGTx
MeiraGTx offers a comprehensive portfolio of products and services, including Riboswitch Platform, Vector Optimization, and End-to-end Manufacturing Ecosystem. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables precise control of transgene expression for therapeutic applications.
Improves potency and safety of genetic vectors for disease treatment.
Supports full-scale manufacturing of genetic therapies for clinical use.
Unlock access to complete
Funding Insights of MeiraGTx
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $30.0M
-
First Round
First Round
(27 Feb 2019)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - MeiraGTx | Valuation |
investors |
|
| Feb, 2019 | Amount | Post-IPO - MeiraGTx | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MeiraGTx
MeiraGTx has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Johnson & Johnson Innovative Medicine, Sanofi and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MeiraGTx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MeiraGTx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Meiragtx Comparisons
Competitors of MeiraGTx
MeiraGTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Biogen, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Meiragtx
Frequently Asked Questions about MeiraGTx
When was MeiraGTx founded?
MeiraGTx was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Where is MeiraGTx located?
MeiraGTx is headquartered in New York, United States. It is registered at New York, New York, United States.
How many employees does MeiraGTx have?
As of Dec 31, 2024, the latest employee count at MeiraGTx is 381.
What is the annual revenue of MeiraGTx?
Annual revenue of MeiraGTx is $33.28M as on Dec 31, 2024.
What does MeiraGTx do?
MeiraGTx was founded in 2015 in New York, United States, and operates in the biotechnology sector focused on gene therapies. Investigational treatments are advanced for ocular disorders, including AAV-RPGR for X-linked retinitis pigmentosa and AAV-RPE65 for a rare pediatric condition. Neurodegenerative applications are also pursued, such as AAV-GAD for Parkinsons disease, with clinical development ongoing across these areas.
Who are the top competitors of MeiraGTx?
MeiraGTx's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does MeiraGTx offer?
MeiraGTx offers Riboswitch Platform, Vector Optimization, and End-to-end Manufacturing Ecosystem.
Is MeiraGTx publicly traded?
Yes, MeiraGTx is publicly traded on NASDAQ under the ticker symbol MGTX.
Who are MeiraGTx's investors?
MeiraGTx has 5 investors. Key investors include Johnson & Johnson Innovative Medicine, Sanofi, Orbimed, Perceptive Advisors, and Johnson & Johnson Innovation.
What is MeiraGTx's ticker symbol?
The ticker symbol of MeiraGTx is MGTX on NASDAQ.